None listed
Conditions
Interventions
AMOXICILLIN + AMBROXOL POWDER FOR ORAL SUSPENSION Type of group
Pharmaceutical Form and route of administration: Powder for Oral Suspension.
Orally
Treatment Dosage and Frequencies: 50 mg / kg / day divided into two doses every 12 hours. Maximum dose: 1 g / day.
Group name:AMOXICILIN POWDER FOR ORAL SUSPENSION Type of group
TREATMENT OF UPPER AND LOWER RESPIRATORY INFECTIONS CAUSED BY SENSITIVE GERMS.
POWDER FOR ORAL SUSPENSION
50ML/KG/DAY DIVIDED INTO 2 DOSES EVERY 12 HOURS. MAXIMUM 1G/DAY
Sponsors
Instituto Quimioterapico S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: Patients between 2 - 15 years - Clinical diagnosis of bacterial pharyngotonsillitis (4 or more McIsaac Modified Centor criteria) with rapid antigenic detection test for positive or negative GABHS, or less than 4 McIsaac Modified Centor criteria with positive GABHS rapid antigenic detection test. - Signed informed consent form. - Negative SARS COV-2 Rapid Test
Exclusion criteria
Exclusion criteria: - Concomitant respiratory infections such as acute otitis media, acute sinusitis, pneumonia, subpharyngeal infections or tonsillar abscesses. - History of rheumatic heart disease or valve dysfunction of unknown etiology - Immunosuppression - Skin rash - Compromise of kidney or liver function. - Patients with some type of cancer. - History of recurrent or recent pharyngotonsillitis (more than 3 episodes in the last 6 months or 1 episode in the last month) - Have received oral antibiotics in the last 7 days prior to enrollment in the study or have received cephalosporins in the last three months. - History of hypersensitivity to amoxicillin or type 1 hypersensitivity to penicillin. - History of hypersensitivity to ambroxol. - Pregnancy or lactation. - Concurrent treatment with another antibiotic or with corticosteroids.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Norrby GABHS Symptom Assessment Scale for Pharyngotonsillitis. Rapid antigenic detection test for GABHS. Measure:Improved clinical evaluation and microbiological cure Timepoints:10 and 15 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Symptom assessment scale for GABHS pharyngotonsillitis Measure: Improved clinical evaluation of symptom Timepoints:3 day ; Outcome name:EAS report Measure:EAS rnumbers Timepoints:to 15 days | — |
Countries
Peru
Contacts
Public ContactRAUL YEPEZ
PERUVIAN CLINICAL RESEARCH S.A.C
Outcome results
None listed